| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 32.7MM | -2% |
| Operating Income | -13.2MM | -54% |
| Operating Expenses | 45.9MM | - |
| Net Income | -13.4MM | -54% |
| R&D | 4.4MM | -19% |
| G&A | 13MM | +4% |
| Marketing | 4.5MM | -37% |
| Amortization | 916K | -32% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
BioLife Solutions Inc (NASDAQ:BLFS) Chief Marketing Officer Todd Berard has sold 10,000 shares of the company on April 15, 2024, according to a recent SEC Filing.
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") and the broader biopharma markets, today announced that it has completed the divestiture of its wholly owned subsidiary Global Cooling, Inc. ("GCI" or "Stirling").
BioLife Solutions, Inc. ( NASDAQ:BLFS ) shareholders should be happy to see the share price up 14% in the last quarter...
In this article, we will take a detailed look at Corporate Insiders Are Selling These 10 Small-Cap Stocks. For a quick overview of such stocks, read our article Corporate Insiders Are Selling These 5 Small-Cap Stocks. When the inflation crisis started and the Federal Reserve began raising interest rates, investors were quick to exit small-cap stocks which are deemed […]
BioLife Solutions Inc (NASDAQ:BLFS), a leading developer, manufacturer, and supplier of bioproduction tools and services for cell and gene therapies, has reported an insider sale according to a recent SEC filing.
BioLife Solutions Inc (NASDAQ:BLFS), a leading developer, manufacturer, and supplier of bioproduction tools and services for cell and gene therapies, has reported an insider sell according to the latest SEC filings.
BioLife Solutions, Inc. ( NASDAQ:BLFS ) is possibly approaching a major achievement in its business, so we would like...
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced that Roderick de Greef, Chief Executive Officer, and Troy Wichterman, Chief Financial Officer, will present and meet with current and prospective investors at the following March Investor Conferences.
BioLife Solutions, Inc. (NASDAQ:BLFS) Q4 2024 Earnings Call Transcript February 29, 2024 BioLife Solutions, Inc. beats earnings expectations. Reported EPS is $-0.3, expectations were $-0.36. BioLife Solutions, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, ladies and […]
Q4 2023 BioLife Solutions Inc Earnings Call